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Despite advances in the treatment of cancer, the death rate remains
high. In 2005, more than 153000 people died from the disease in
the United Kingdom (http://info.cancerresearchuk.org/cancerstats/
mortality/?a¼5441); hence anticancer therapies with novel me-
chanisms of actions are urgently needed. Gene therapy is one
promising candidate. Conventional cancer treatments often lack
selectivity for tumour cells, leading to toxicity. By contrast, gene
therapy allows for the targeting of anticancer agents to the
malignant cells, thus minimising damage to normal tissues. An
advantage of cancer gene therapy is that it does not require long-
term transgene expression, unlike gene therapy for many non-
cancer diseases. This is one reason why two-thirds of all gene
therapy trials so far have focused on the treatment of cancer
(www.wiley.co.uk/genmed/clinical). However, the initial enthu-
siasm for cancer gene therapy has been dampened by an increasing
number of obstacles that need to be overcome before it can be used
routinely in the clinic. Cancer gene therapy has reached a critical
stage and the editors of Gene Therapy for Cancer have identified
the need for this book that covers the current technologies of
cancer gene therapy as well as the difficult task of applying these in
clinical trials.
The book has 67 contributors, mostly based in the United States.
It contains over 450 pages of text, divided into three parts:
(1) vectors used in gene therapy against cancer, (2) targets and
specific approaches for the therapy of cancer and (3) clinical
applications of cancer gene therapy. These sections are subdivided
into 25 chapters, each of which is written by well-recognised
experts on the topic, and prefaced by a summary of the chapter
and a list of key words. Gene Therapy for cancer includes
references up to and including 2004. This reflects the period of
time that it takes to complete a multi-authored book. One criticism
is that as cancer gene therapy is a rapidly advancing technology,
the developments of the last 3 years in this field are absent. The
index is extensive, making it easy to find specific information.
The book also benefits through its helpful tables, drawings and
illustrations.
The first part of the book gives a good overview of the vector
systems that have been developed for cancer gene therapy,
describing their respective characteristics and production meth-
ods. Nonreplicating and oncolytic adenoviral vectors are discussed
in chapter 1, followed by a chapter that describes the immu-
nogenicity of these vectors and the pathways of adenoviral
infection. Chapter 3 deals with lentiviral and retroviral vector
systems (both replicating and nonreplicating), with emphasis on
safety considerations. Vaccinia and pox virus vectors are discussed
in chapter 4, while chapter 5 describes the development of
herpesvirus vectors for clinical applications. Chapter 6 addresses
the different types of alphavirus vectors (replication-deficient,
replicating and DNA-based). In chapter 7, vesicular stomatitis
virus and other RNA viruses are discussed (reovirus, measles,
Newcastle disease virus, influenza virus and poliovirus). There is
also a chapter on parvoviral vectors (autonomous parvoviruses
and adeno-associated virus; chapter 8), before the first part of
Gene Therapy for Cancer concludes with an overview over nonviral
gene delivery systems (chapter 9).
The second part of the book introduces a range of different
strategies and targets for cancer gene therapy. It begins with a
review of oncogenes, tumour suppressor and apoptosis-inducing
genes, and their applications in cancer gene therapy (chapter 10).
Chapter 11 then describes gene-silencing approaches, focusing on
RNA interference. There are also three chapters dealing with
oncolytic viruses; strategies for the re-targeting of adenoviral
vectors to tumour cells are discussed in chapter 12, while chapters
13 and 19 discuss oncolytic Herpes simplex vectors and the
adenovirus D24, respectively. Some of the topics that are discussed
in these three chapters have already been covered in the first part
of the book and are repetitive. In chapter 14, cell-based and active
vaccination strategies to deliver cytokine genes are discussed.
Chapter 15 describes combination treatments with cancer gene
therapy and conventional radiotherapy, followed by a chapter
addressing gene transfer strategies for haematopoietic stem cells.
Nonviral gene delivery for genetic vaccines is reviewed in chapter
17 and finally, approaches to inhibit tumour angiogenesis and
lymphangiogenesis are described in chapter 18. It is notable that
there is comparatively little discussion of approaches that utilise
prodrug-activating enzymes in the second part of the book. The
field of cancer gene therapy is vast and it impossible to consider
every strategy, but a more thorough overview could have been
achieved by devoting a whole chapter to this topic.
In the third and last part, the book focuses on cancer gene
therapies that have reached the clinical testing stage. The chapters
in this section are authored by experts on clinical trials who
discuss the difficulties of translating preclinical findings into
clinical results and present ways to overcome some of these
challenges. Since the approval of the first clinical cancer gene
therapy trial in 1989, over 800 trials have been carried out
worldwide (www.wiley.co.uk/genmed/clinical). Chapter 20 pro-
vides a comprehensive overview of the outcome of these studies,
discussing issues such as efficacy, side effects and response
indicators. This chapter also gives an insight into the future
directions in the field. Chapters 21 and 24 both describe preclinical
and clinical data for E1A gene therapy. In chapter 22, the clinical
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reviewed, and chapter 23 discusses mda-7 (IL-24) gene transfer,
focussing strongly on preclinical data. The last chapter of the book
(chapter 25, written by two of the editors) summarises and reviews
all of the steps from the preclinical phase to clinical trial
completion; although the regulatory and financial considerations
in this chapter will appeal mainly to researchers in the United
States, they are not without relevance in Europe.
In summary, Gene Therapy for Cancer provides a good overview
of currently available techniques for cancer gene therapy and their
limitations and potential for clinical applications. The book is a
useful addition to the library of both researchers and clinicians
working in the field.
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